---
title: "Liminatus Pharma (LIMN.US) — 财务报表"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/LIMN.US/norm.md"
symbol: "LIMN.US"
name: "Liminatus Pharma"
parent: "https://longbridge.com/zh-CN/quote/LIMN.US.md"
datetime: "2026-03-06T08:34:49.724Z"
locales:
  - [en](https://longbridge.com/en/quote/LIMN.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LIMN.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LIMN.US/norm.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/LIMN.US/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/LIMN.US/norm.md)


# Liminatus Pharma (LIMN.US) — 财务报表

## 利润表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 每股收益 | -0.0675 | 0.0049 | 0.0000 | -0.0020 | -0.0344 |
| ROE | 139.54% | -10.29% | 0.01% | - | - |
| 营业收入 | - | - | - | - | - |
| 净利润 | -1.82M | 113287.00 | -255.00 | -229000.00 | -601372.00 |
| 营业利润 | -701170.00 | -1.12M | -255.00 | -167000.00 | -543147.00 |
| 毛利率 | - | - | - | - | - |
| 净利率 | - | - | - | - | - |
| 利润含金量 | - | - | - | - | - |

## 资产负债表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 资产与负债 | 1.34M | 1.91M | - | 5.41M | 4.51M |
| 权益乘数 | -0.8157 | -0.2167 | - | -0.2797 | -0.2360 |
| 每股净资产 | -0.0608 | -0.3386 | 0.0000 | -0.1723 | -0.1703 |
| 资产周转率 | - | - | - | - | - |
| 现金及短投 | 724502.00 | 1.34M | - | 56000.00 | 47000.00 |
| 存货与应收 | - | - | - | - | - |
| 长期投资 | 12764.00 | 198.00 | - | 1000.00 | 1000.00 |
| 净债务 | 717998.00 | 104278.00 | - | 19.92M | 19.23M |

## 现金流量表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 经营现金流 | -600612.00 | -8.98M | 0.0000 | -141000.00 | -206119.00 |
| 投资现金流 | -13108.00 | -775000.00 | - | -550000.00 | -800000.00 |
| 融资现金流 | 0.0000 | 11.03M | - | 700000.00 | 1.02M |
| 自由现金流 | -8.14M | - | - | - | - |
| 现金流充裕率 | -4582.03% | -690.45% | - | - | - |
| 举债与偿债 | 0.0000 | 4.34M | - | 700000.00 | 983000.00 |
| 资本支出 | -13108.00 | - | - | - | - |